<DOC>
	<DOCNO>NCT01250470</DOCNO>
	<brief_summary>This phase I trial study side effect vaccine therapy give together sargramostim treat patient malignant glioma . Vaccines make survivin peptide may help body build effective immune response kill tumor cell . Colony-stimulating factor , sargramostim , may increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy sargramostim may better treatment malignant glioma .</brief_summary>
	<brief_title>Vaccine Therapy Sargramostim Treating Patients With Malignant Glioma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine toxicity profile SVN53-67/M57-KLH peptide Montanide ISA 51 ( Montanide ISA-51/survivin peptide vaccine ) plus GM-CSF ( sargramostim ) . SECONDARY OBJECTIVES : I . To measure immune response induce SVN53-67/M57-KLH Montanide ISA 51 GM-CSF . TERTIARY OBJECTIVES : I . To collect preliminary data therapeutic efficacy combination malignant glioma . OUTLINE : Patients receive Montanide ISA-51/survivin peptide vaccine subcutaneously ( SC ) follow sargramostim SC day 0 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow week 12 , 16 , 20 , 24 . TREATMENT EXTENSION : After completion study treatment , select patient may receive additional dos Montanide ISA-51/survivin peptide vaccine SC sargramostim SC . Treatment repeat every 3 month absence disease progression unacceptable toxicity . After completion treatment extension , patient follow 1 month .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Histologic proof one following : glioblastoma multiforme , anaplastic astrocytoma , anaplastic oligodendroglioma anaplastic mixed glioma anaplastic oligoastrocytoma Must recurrent progressive disease follow standard therapy Karnofsky performance status ( KPS ) great equal 70 Human leukocyte antigen ( HLA ) A *02 HLAA *03 blood cell haplotype document polymerase chain reaction ( PCR ) analysis flow cytometry Survivin expression patient 's tumor cell document immunohistochemistry Must free systemic infection ; subject active infection ( whether require antibiotic therapy ) may eligible complete resolution infection ; subject antibiotic therapy must antibiotics least 7 day begin treatment White blood count &gt; = 3000/mm^3 Platelets &gt; = 100,000/mm^3 Hemoglobin &gt; = 10.0 g/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal ( ULN ) Total bilirubin = &lt; 2.0 mg/dL Serum creatinine = &lt; 1.5 x institutional upper limit normal ( ULN ) Patients childbearing potential must agree use acceptable contraceptive method treatment three month completion ; woman must negative serum pregnancy test Patients recent cranial surgery eligible inclusion , vaccine may administer prior postoperative day 14 Patient legal representative must able read , understand investigational nature study sign Institutional Review Board approve write informed consent form prior receive study related procedure Inability obtain histologic proof malignancy material unavailable survivin test Systemic corticosteroid therapy &gt; 12 mg dexamethasone equivalent per day study entry ; patient stable dose HLAA *02 HLAA *03 negative Active infection require treatment ( include human immunodeficiency virus [ HIV ] infection ) Any medical condition , opinion principal investigator , would compromise patient 's ability participate study ; include chronic active hepatitis infection , immunodeficiency disease , concurrent neurological condition autoimmune disease Any following : pregnant nursing woman , woman childbearing potential sexual partner unwilling employ effective contraception ( condom , diaphragm , birth control pill , injection , intrauterine device , surgical sterilization , subcutaneous implant abstinence ) Concurrent chemotherapy , immunotherapy , radiotherapy , radiosurgery , interferon ( e.g . IntronA ) , allergy desensitization injection ; growth factor ( e.g . Procrit , Aranesp , Neulasta ) , interleukin ( e.g . Proleukin ) investigational therapeutic medication Evidence current drug alcohol abuse psychiatric impairment , investigator 's opinion prevent completion protocol therapy followup Use experimental drug reason within 30 day , standard care drug therapy within 28 day prior randomization , failure fully recover hematological effect prior chemotherapy Known allergy hypersensitivity keyhole limpet hemocyanin ( KLH ) , GMCSF magnetic resonance imaging ( MRI ) contrast agent Life expectancy le 4 month Any prior autoimmune disorder require cytotoxic immunosuppressive therapy , autoimmune disorder visceral involvement ; participant mild arthritis require nonsteroidal antiinflammatory drug ( NSAID ) medication exclude Participants another cancer diagnosis ineligible , except : squamous cell cancer skin without know metastasis , basal cell cancer skin without know metastasis , carcinoma situ breast ( ductal carcinoma situ [ DCIS ] lobular carcinoma situ [ LCIS ] ) , carcinoma situ cervix cancer without distant metastasis treat successfully , without evidence recurrence metastasis 5 year Unwilling unable follow protocol requirement Any condition investigator 's opinion deem patient unsuitable candidate receive study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>